|
1) 日本透析医学会統計調査委員会. わが国の慢性透析療法の現況(2006年末の慢性透析患者に関する基礎集計)
|
|
|
|
|
2) Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003; 63: 225-32
|
|
|
|
|
3) Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003; 348: 383-93
|
|
|
|
|
|
4) Asselbergs FW, Hillege HL, van Gilst WH, et al. Framingham score and microalbuminuria: combined future targets for primary prevention？ Kidney Int. 2004; 92: S111-4
|
|
|
|
|
|
5) 日本糖尿病学会. 科学的根拠に基づく糖尿病診療ガイドライン. 東京; 南江堂: 2004
|
|
|
|
|
|
6) Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hyper-tension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000; 36: 646-61
|
|
|
|
|
|
7) Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephro-pathy due to type 2 diabetes. N Engl J Med. 2001; 345: 851-60
|
|
|
|
|
|
8) Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345: 861-9
|
|
|
|
|
|
9) Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001; 345: 870-8
|
|
|
|
|
|
10) Viberti G, Wheeldon NM, MicroAlbuminuria Reduction with VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002; 106: 672-8
|
|
|
|
|
|
11) 曽根博仁, 山田信博, JDCSグループ. 日本人の糖尿病治療の前向き研究 Japan Diabetes Complications Study (JDCS). 内科. 2006; 97: 16-21
|
|
|
|
|
12) Wu AY, Kong NC, de Leon FA, et al. An alarm-ingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the Micro-Albuminuria Prevalence (MAP) Study. Diabetologia. 2005; 48: 17-26
|
|
|
|
|
|
13) 荻原俊男, 南芙美子, 甲斐沼正, 他. 高血圧患者におけるアンジオテンシンII受容体拮抗薬BIBR277(テルミサルタン)の薬物動態試験. 薬理と治療. 2002; 30(Suppl 1): S271-83
|
|
|
|
|
|
14) Kurtz TW, Pravenec M. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. J Hypertens. 2004; 22: 2253-61
|
|
|
|
|
|
15) Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension. 2004; 3: 993-1002
|
|
|
|
|
|
16) Miura Y, Yamamoto N, Tsunekawa S, et al. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes. Metabolic and antiatherogenic consequences. Diabetes Care. 2005; 28: 757-8
|
|
|
|
|
|
17) Vitale C, Mercuro G, Castiglioni C, et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol. 2005; 4: 6
|
|
|
|
|
|
18) Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004; 351: 1952-61
|
|
|
|
|
|
19) Schmieder RE, Delles C, Mimran A, et al. Impact of telmisartan versus ramipril on renal endo-thelial function in patients with hypertension and type 2 diabetes. Diabetes Care. 2007; 30: 1351-6
|
|
|
|
|
|
20) Makino H, Haneda M, Babazono T, et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care. 2007; 30: 1577-8
|
|
|
|
|
|
21) Kurokawa K, et al. Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 deabetes: a subanalysis of Japanese patietnts from the RENAAL study. Clin Exp Nephrol. 2006; 69: 193-200
|
|
|
|
|